ImmunoGen Unable To Ride Kadcyla Wave For Long; Disappoints Investors
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech is fresh off the approval of a highly anticipated breast cancer treatment, which oncology powerhouse Roche/Genentech is commercializing, but investors are already shifting their focus to the company’s lead asset, which has been made riskier by the appearance of a safety signal in Phase II.